The EVII gene, located at chromosome band 3q26, is overexpressed in some myeloid leukemia patients with breakpoints either 5' of the gene in the t(3;3)(q21;q26) or 3' of the gene in the inv(3)(q21q26). EVIl is also expressed as part of a fusion transcript with the transcription factorAMLI in the t(3;21)(q26;q22), associated with myeloid leukemia. In cells with t(3;21), additional fusion transcripts are AMLIMDSl andAMLI-MDSI-EV71.MDSJ is located at 3q26 170-400 kb upstream (telomeric) The protooncogene EVI1 was initially identified and described in the mouse. It is activated in murine myeloid leukemia by proviral insertion in the evil common integration site (1, 2). EVIl is not normally expressed in hematopoietic cells. In humans, the gene can be activated in myeloid leukemias and myelodysplastic diseases by chromosomal rearrangements either 5' of the gene in the t(3;3)(q21;q26) or 3' of the gene in the inv(3)(q21q26) by juxtaposition of the gene to enhancer elements of the ribophorin gene located at 3q21 (3-5). Activation of EVIl can also occur in the t(3;21)(q26;q22) as part of the fusion mRNA,AMLl-EV71, that is transcribed from the der(3) chromosome (6, 7). Abnormal expression of EVI1 has also been detected in patients with myeloid leukemia and a cytogenetically normal karyotype (8), suggesting that inappropriate activation of this gene occurs through various mechanisms.
MDSl andAMLI-MDSI-EV71.MDSJ is located at 3q26 170-400 kb upstream (telomeric) of EVIl in the chromosomal region in which some of the breakpoints 5' of Efil have been mapped. MDS1 has been identified as a single gene as well as a previously unreported exon(s) of EVII. We have analyzed the relationship between MDSl and EVII to determine whether they are two separate genes. In this report, we present evidence indicating that MDSl exists in normal tissues both as a unique transcript and as a normal fusion transcript with EVIl, with an additional 188 codons at the 5' end ofthe previously reportedEMI open reading frame. This additional region has about 40% homology at the amino acid level with the PR domain of the retinoblastomainteracting zinc-finger protein RIZ. These results are important in view of the fact that EVIl and MDSI are involved in leukemia associated with chromosomal translocation breakpoints in the region between these genes.
The protooncogene EVI1 was initially identified and described in the mouse. It is activated in murine myeloid leukemia by proviral insertion in the evil common integration site (1, 2). EVIl is not normally expressed in hematopoietic cells. In humans, the gene can be activated in myeloid leukemias and myelodysplastic diseases by chromosomal rearrangements either 5' of the gene in the t(3;3)(q21;q26) or 3' of the gene in the inv(3)(q21q26) by juxtaposition of the gene to enhancer elements of the ribophorin gene located at 3q21 (3) (4) (5) . Activation of EVIl can also occur in the t(3;21)(q26;q22) as part of the fusion mRNA,AMLl-EV71, that is transcribed from the der(3) chromosome (6, 7) . Abnormal expression of EVI1 has also been detected in patients with myeloid leukemia and a cytogenetically normal karyotype (8) , suggesting that inappropriate activation of this gene occurs through various mechanisms.
EV71 is a nuclear protein containing a seven-zinc-finger domain at the N-terminal end, a three-finger domain in the central part of the molecule, and an acidic domain distal to the second group of zinc fingers (9) . The human and mouse open reading frames are 91% homologous at the DNA level and 94% homologous at the amino acid level. The second exon of the gene, in frame although not translated, is highly conserved between the two species. The open reading frame starts in the third exon of the gene, where the first ATG is located (9) . A The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. putative promoter has been identified, by genomic sequencing and Si protection analysis, immediately upstream of the first exon of the murine cDNA (10).
MDS1 was cloned as one of the partner genes of AML1 in the t(3;21)(q26;q22), associated with therapy-related acute myeloid leukemia and myelodysplastic syndrome as well as with chronic myeloid leukemia in blast crisis (11, 12) . In this translocation, AML1, located at 21q22, is fused to several genes, EAP, MDS1, and EVIl, all of which are located at 3q26
200-400 kb apart (7), and chimeric cDNAs have been isolated from cells with t(3;21) in which AML1 is fused to EAP, to MDS1, to EVI1, or to MDS1 and EVIl in the same transcript, producing, in the latter case, a very complex chimeric gene. Only the 3' region of MDS1 that is fused to AML1 has been isolated and sequenced. The nature of MDS1 is somewhat controversial; MDS1 has been described as a unique gene (7) , and also as one or more previously unreported exons of EVIl (6) . MDS1 has been mapped 170-400 kb upstream of EVIl (7); if it were part of EVI1, then EVIl would have two promoters separated by hundreds of kilobases. The existence of genes with multiple promoters is not unusual and has been documented in other cases (11, 12 (13) .
MATERIALS AND METHODS
Screening cDNA Libraries and cDNA Sequencing. The pancreas cDNA library was purchased from Stratagene and was used according to the manufacturer's instructions. The kidney cDNA library, prepared in Agt1O, was the generous gift of Graeme Bell (University of Chicago, Chicago). Both libraries were screened with the PCR-amplified MDS1 probe. The probe and the primers used for PCR amplification have been described (7) . The isolated from a t(3;21) patient (7) . The two genes involved in the chimeric transcript are AML1 and MDSI. The 1.5-kb region downstream of the chimeric junction with AML1 corresponds to the distal part of an MDS1 transcript. The 5' end of MDS1A had not been cloned. The 1.5-kb region represents a 3' end of MDS1, and it is indicated as MDSJA in Fig. 1 and  3 . We used the MDS1 probe (Fig. 1) Analysis ofthe 3' ends ofthe pancreas library clones. Based on the size of the inserts, the pHP cDNA clones were divided into two groups, one with inserts between 1.3 and 1.4 kb (pHP5 and pHP6) and the second group with insert of 4-4.3 kb (pHP1, pHP2, and pHP7). All five pHP clones were completely sequenced. pHP5 and pHP6 were identical and diverged sharply from MDS1A, as well as from pHP1, pHP2, and pHP7 at nt 682. Fig. 3 shows the DNA sequence alignment of MDS1A and pHP6. After nt 682, pHP5 and pHP6 continued for -660 nt with no significant homology to sequences deposited in GenBank. The region of the divergence, between nt 680 and 686 of MDS1A, matches that of a splice donor site (indicated in boldface in Fig. 3 ). We concluded that pHP6 represented an alternative splice form of MDS1 obtained by utilization of the splice donor consensus site with another exon(s) located farther downstream, and we called it MDS1B. The sequence of pHP5 was a few nucleotides shorter than that of pHP6 at the 5' and 3' ends. MDSlB encodes a 169-amino acid mostly hydrophilic polypeptide with a predicted mass of 19 kDa, with 26% acidic and basic residues, and with 20% proline and serine residues. Between nt 346 and 682, MDSlB is identical to 341 nt of the MDS1A (Fig. 3) , which is defined at the 5' end by the fusion junction with AMLI detected in the AMLJ-MDS1
(arrowhead in Fig. 3 ), and at the 3' end by a splice consensus site (Fig. 3 , nt 680-686 in bold face type). The sequence of MDSIB and MDS1A downstream of the splice consensus site diverged. MDSlB reading frame continued with 44 codons and MDS1A reading frame for 14 codons for before termination (stop codons underlined in Fig. 3) . Downstream of the stop codons, the 3' untranslated sequences of MDS1B and MDS1A were AT-rich and contained putative signals for selective destabilization in both of them (ATTTA, doubly underlined in Fig. 3 ), a consensus polyadenylylation signal was detected for MDS1A (AATAAA, doubly underlined in Fig. 3 ) and potenProc. Natl. Acad. Sci. USA 93 (1996) tial polyadenylylation signals were detected for MDS1B (CATAAA and TATAAA, doubly underlined, Fig. 3 ). The sequence of the longer clones (pHP1, pHP2, and pHP7) also diverged from MDSJA after nt 682 (splice donor site) and continued for -2.4 kb. After nt 682, MDS1 was fused in-frame to the second exon of EV1l (Figs. 1 and 3) . Downstream of the splice donor site, pHP2 and pHP7 were identical to the sequence of EVII cDNA (9) except for nine base-pair differences, as was detected by Mitani et al. (6) in their EVIl sequence. The sequence of pHP2 and pHP7 encoded a polypeptide of 1240 residues. This alternative form of EVI1 contains an additional 188 residues at the N-terminal end, 125 of which are encoded by MDSI, and 63 are encoded by the second and part of the third exons of EVI1. pHP1 had a deletion from nt 2194 to 2308 of the published sequences (data not shown). The deletion introduced a frame shift in the reading frame and a stop codon upstream of the second group of zinc fingers or the acidic domain. Interestingly, the 3' end of the sequence of pHP1, pHP2, and pHP7, as well as the two EVI1 cDNAs reported by Morishita et al. (9) and by Mitani et al. (6), terminated with the exactly same nucleotide. A diagram of the various cDNAs is shown in Fig. 1 .
Analysis ofthe kidney library clones. PCR analysis of 10 of the 17 phage clones isolated from the human kidney library (HK1 to HK10) and one strand sequencing of the fragments PCRamplified with primer 1 and a vector-specific primer showed that the 5' end of the 10 clones contained the purine-rich region and GA repeats as seen for pHP6. The 3' region of the phages was analyzed by PCR, with either primers 2 and 3, specific for MDS1B, or primers 2 and 4, which amplify the MDS1-EVI1 junction (Figs. 1 and 3) . The size of the separated reaction products were compared to those obtained by PCR with pHP2 and pHP6 used as controls. Three of the 10 phage clones corresponded to pHP6, whereas the 7 remaining clones corresponded to pHP2. To confirm that the 7 clones contained EVIl sequence and to determine whether they had a deletion at the 3' end similar to that detected in pHP1, we analyzed them by PCR with primers 5 and 6, flanking the deletion observed in pHP1 (ref. 3 and Fig. 1) . A band corresponding to the size of the normal non-deleted sequence was noted (results not shown). Thus, we concluded that 3 of the clones contained MDS1 only, and the remaining 7 clones contained MDSJ-EVIl (results not shown). We did not isolate any clone corresponding to MDS1A in either of the cDNA libraries that we screened, indicating that the spliced form MDS1A isolated from a leukemic patient with a t(3;21) is not the one preferentially expressed in kidney or pancreas. The kidney clones were not analyzed further.
Expression of MDSI and EVIl in Normal Human Tissues. We analyzed three commercially prepared multiple-humantissue Northern blots with probes specific for the two genes. By using an EVI1 probe, three major bands of 6.5, 5.8, and 5 kb were identified in two of the blots (Fig. 4A) . This pattern and the size of bands has been reported (9) for EVI1. By using the MDSI probe, a major band of 6.5 kb and a much fainter band of -5.8 kb were also detected in both blots after a longer exposure (Fig. 4B Upper) . We assigned the larger band identified by both probes to the MDSI-EVIl transcript. In addition, the MDS1 probe identified more intense unique bands of approximately 2, 1.5, and 1 kb after shorter exposure time (Fig.   4B Lower) . We assigned the 2-kb band to the MDSJA transcript and the 1.5-kb band to the MDS1B transcript. The smallest 1-kb band could represent an additional isoform of MDSI. The EVIl probe identified a unique transcript of -5 kb in addition to the 6.5-kb and 5.8-kb bands. These three bands have been previously seen by other groups. The results for the third blot differed from those of the other two blots: they showed only one band corresponding to a transcript of -6.5 kb after hybridization to the EVIl probe, and no smaller transcript with the MDS1 probe. We have no explanation for the different results obtained with the third blot, other than that perhaps the quality of the mRNA was not satisfactory. RNase Protection Analysis and Primer Extension Analysis.
The location of the RNA probe used for the protection assay is shown in Fig. 1 Fig. 1 '-. 5 ., .,l, X --N--extending upstream from the third exon is the largest one of -1.6 kb. This band is a doublet, and its nature is still under investigation. We have assigned the three remaining bands to fragments shown in Fig. 6 Lower. Whereas the 0.27-, 0.9-, and 1.6-kb bands seem compact, the 0.4-kb band appears diffused, suggesting that there could be several minor sites where initiation of transcription occurs. Of the three assigned fragments, the one of 0.9 kb seems to be the most abundant, and conservation of the second exon between human and murine cDNAs. During revision of the manuscript, a GenBank homology search showed that the predicted translation product of the distal part of MDSI combined to the second exon of EVI1 is 40% homologous to the amino end of the recently cloned retinoblastoma binding protein RIZ (14) and, to a lesser extent, to the PR domain of the transcription repressor PRDI-BF1/Blimp-1, that can drive B-cell differentiation and to the Caenorhabditis elegans zinc-finger protein egl-43. egl-43 has also extensive homology to EVIl in the zinc-finger regions, suggesting that overall the two proteins are evolutionarily conserved. Analysis of the conserved residues in the PR domain (Fig. 7) showed that they can be divided into three blocks, A, B, and C. These blocks are of 12 amino acids and are evenly separated by a stretch of less conserved sequences of '30 amino acids. The fact that the homology region spans MDSJ and the first part of EVI1 supports our hypothesis that the two genes can also encode one single protein. It is of interest to note that in the t(3;3) and t(3;21), the chromosomal breakpoints occur between MDS1 and EVI1, thus separating the PR domain from EVIl. The role of the three genes in normal cells are currently analyzed in our laboratory. Clearly much work needs to be done to determine how alterations in these two gene contribute to leukemia.
